China SXT Pharmaceuticals (SXTC) Retained Earnings: 2018-2025
- China SXT Pharmaceuticals' Retained Earnings fell 34.76% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.4 million, marking a year-over-year decrease of 34.76%. This contributed to the annual value of -$28.0 million for FY2025, which is 13.37% down from last year.
- China SXT Pharmaceuticals' Retained Earnings amounted to -$34.4 million in Q3 2025, which was down 22.73% from -$28.0 million recorded in Q1 2025.
- China SXT Pharmaceuticals' 5-year Retained Earnings high stood at -$10.0 million for Q1 2021, and its period low was -$34.4 million during Q3 2025.
- For the 3-year period, China SXT Pharmaceuticals' Retained Earnings averaged around -$27.6 million, with its median value being -$26.8 million (2024).
- In the last 5 years, China SXT Pharmaceuticals' Retained Earnings plummeted by 124.02% in 2021 and then rose by 18.51% in 2024.
- Over the past 5 years, China SXT Pharmaceuticals' Retained Earnings (Quarterly) stood at -$13.0 million in 2021, then tumbled by 31.73% to -$17.2 million in 2022, then tumbled by 82.21% to -$31.3 million in 2023, then grew by 18.51% to -$25.5 million in 2024, then crashed by 34.76% to -$34.4 million in 2025.
- Its Retained Earnings was -$34.4 million in Q3 2025, compared to -$28.0 million in Q1 2025 and -$25.5 million in Q3 2024.
